Table 3.
Ongoing pharmacological treatment in studied groups
| Pharmacological treatment | Number of patients receiving treatment | ||
| OSAS, n = 27 | CPAP-OSAS, n = 22 | Controls, n = 11 | |
| ACEI | 12 | 10 | 2 |
| Diuretics | 11 | 6 | 1 |
| Ca2+ channel blocker | 4 | 5 | 1 |
| Beta-blockers | 4 | 1 | 1 |
| Nitrates | 4 | 4 | 1 |
| Digitalis | 3 | 1 | 0 |
| Statins | 8 | 6 | 0 |
| Allopurinol | 0 | 4 | 0 |
| Ticlopidine | 2 | 0 | 1 |
| Gliclazide | 1 | 5 | 0 |
ACEI – angiotensin converting enzyme inhibitors; OSAS – patients with untreated OSAS; CPAP-OSAS – patients with OSAS treated successfully after a first attempt with CPAP, controls – subjects without OSAS. Four, 2, and 6 subjects were free of any medication in OSAS, CPAP-OSAS and controls group, respectively.